Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Why are cancer clinical trials important? Find out in this video interview with Dr. Rebecca Auer.
Canadian Cancer Trials group is providing an update about the previously planned BI.3 trial "A Phase II/III Trial Comparing Cisplatin Plus Acelarin to Cisplatin Plus Gemcitabine in First-Line Treatment of Locally Advanced or Metastatic Biliary Tract Cancer". The BI.3 trial will not be proceeding to move forward through the planned academic consortium as lead by CCTG, the partnering company has made a strategic decision to undertake the study as an industry-sponsored trial.
It is anticipated that RIPPLE (Roster Interface Program and Participants List Environment) version 3.0 will be rolled out on October 19, 2018.
On Wednesday September 19th 2018, CCTG's Director, Dr. Janet Dancey aired on the Blind Date with Knowledge radio show. During her interview Dr. Dancey talks about Evolving Clinical Trials through Collaboration. She discussed how the collaborative study of medical interventions in the treatment of cancer has expanded to also investigate how lifestyle, radiation, surgical, and smoke cessation interventions can affect the entire spectrum of cancer treatment.
Smoragiewicz M, Bogaerts J, Calvo E, Marabelle A, Perrone A, Seymour L, Shalabi A, Siu LL, Tabernero J, Giaccone G. Design and conduct of early clinical studies of immunotherapy agent combinations: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (ONLINE) Ann Oncol mdy398, 2018.
The results of the CCTG LY.16 trial of Rituxmab plus Lenalidomide in Advanced Untreated Follicular Lymphoma (RELEVANCE), recently published in New England Journal of Medicine, has the potential to offer a new treatment option to lymphoma patients, that does not require chemotherapy.
Find out more.
Randomized Phase II Study of Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy.
